Senate BillIntroduced
S 7668: Prohibits the knowing sale of xylazine above a certain weight to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.
What S 7668 does, verified January 8, 2026
The proposed law aims to regulate the sale of xylazine, a pharmaceutical drug used for sedation, anesthesia, muscle relaxation, and analgesia in animals. The law prohibits the sale of xylazine in quantities of fifty grams or more to individuals without proof of its intended use for institutional, veterinary, or scientific purposes. Additionally, the sale of xylazine to individuals under the age of twenty-one is also prohibited. Businesses that knowingly sell, offer for sale, or distribute xylazine in excess of fifty grams must maintain sales records, proof of age, and proof of use from all purchasers. Violations of the law may result in a civil penalty of up to three thousand dollars for the first offense and sixty-five hundred dollars for each subsequent offense. All funds collected from civil penalties will be deposited into the New York State Drug Treatment and Public Education Fund.
Bill journey
1IntroducedCurrent
2In CommitteePending
3First Chamber FloorPending
4Second ChamberPending
5GovernorPending
6ChapteredPending
Last action: REFERRED TO CONSUMER PROTECTION (2026-01-07)Alert me
Quick answers about S 7668
- What is the current status of S 7668?
- As of January 8, 2026, S 7668 is recorded as "Introduced": it has been introduced and is waiting for its first committee hearing or floor vote. The last recorded action, on January 7, 2026, was "REFERRED TO CONSUMER PROTECTION".
- Did S 7668 pass?
- Not yet. S 7668 has been introduced and has not passed either house.
- Who wrote S 7668, and where is it now?
- S 7668 was authored by Sen. Nathalia Fernandez. Its committee of record is Senate Rules.
Author and sponsors
Full contact details, staff, and committees with Connect, $16/moUnlockRecent actions7 total · showing 5
| Jan. 07, 2026 | REFERRED TO CONSUMER PROTECTION |
| Jun. 13, 2025 | COMMITTED TO RULES |
| May. 21, 2025 | ADVANCED TO THIRD READING |
| May. 21, 2025 | AMENDED 7668A |
| May. 20, 2025 | 2ND REPORT CAL. |
Latest bill textIntroduced version, April 28, 2025 · 486 words
STATE OF NEW YORK ________________________________________________________________________ 7668 2025-2026 Regular Sessions IN SENATE April 28, 2025 ___________ Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when printed to be committed to the Committee on Consumer Protection AN ACT to amend the general business law, in relation to prohibiting the sale of xylazine above a certain weight The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The general business law is amended by adding a new section 2 392-k to read as follows: 3 § 392-k. Sale of xylazine. 1. For purposes of this section, the term 4 "xylazine" shall mean a pharmaceutical drug used for sedation, anes- 5 thesia, muscle relaxation, and analgesia in animals such as horses, 6 cattle, and other non-human mammals. 7 2. The provisions of this section shall apply only to the sale, offer 8 for sale, delivery, or distribution of xylazine in quantities of fifty 9 grams or more. 10 3. No corporation, partnership, limited liability company, firm, 11 online platform, or any other business entity doing business within this 12 state shall knowingly sell, offer for sale, or deliver fifty grams or 13 more of xylazine to individuals without proof of its intended use for 14 institutional, veterinary, or scientific purposes. 15 4. No corporation, partnership, limited liability company, firm, 16 online platform, or other business entity doing business within this 17 state shall knowingly sell, offer for sale, or deliver fifty grams or 18 more of xylazine to individuals under the age of twenty-one. 19 5. Any corporation, partnership, limited liability company, firm, 20 online platform, or other business entity doing business within this 21 state which knowingly sells, offers for sale, or distributes fifty grams 22 or more of xylazine, shall require and retain sales records, proof of 23 age, and proof of use from all purchasers. 24 6. Any corporation, partnership, limited liability company, firm, 25 online platform, or other business entity doing business within this EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD02623-05-5S. 7668 2 1 state that violates the provisions of this section by knowingly selling, 2 offering for sale, or delivering fifty grams or more of xylazine shall 3 be subject to a civil penalty of not more than three thousand dollars 4 for a first violation, and sixty-five hundred dollars for each subse- 5 quent violation, recoverable in an action by the attorney general of the 6 state of New York. All funds collected or received by the state from 7 civil penalties imposed under this section shall be deposited in the New 8 York state drug treatment and public education fund established pursuant 9 to section ninety-nine-jj of the state finance law. 10 § 2. This act shall take effect immediately.
Text of S 7668 as introduced, from the official record. Connect Plus keeps every version and highlights what changed.Compare versions